Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. 01177
01177 logo

01177 Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy SINO BIOPHARM (01177) Today? Analysis, Price Targets, and 2026 Outlook.

No data

No data

No data

No data

Growth

Profitability

Efficiency

Wall Street analysts forecast 01177 stock price to rise
0 Analyst Rating
0
Wall Street analysts forecast 01177 stock price to rise
0 Buy
0 Hold
0 Sell
0
Current: 6.060
sliders
Low
0
Averages
0
High
0
0
Current: 6.060
sliders
Low
0
Averages
0
High
0
BofA Securities
BofA Securities
NULL -> Buy
maintain
AI Analysis
2026-02-12
Reason
BofA Securities
BofA Securities
Price Target
AI Analysis
2026-02-12
maintain
NULL -> Buy
Reason
The analyst rating for SINO BIOPHARM (01177.HK) was reiterated at "Buy" by BofA Securities due to the completion of enrollment for Phase III clinical trials of two drugs, TQB2102 and LM302. Notably, LM302 is highlighted as the world's first CLDN18.2 antibody-drug conjugate (ADC) to reach this stage, which could provide new treatment options for patients. This development is seen as a positive factor, leading to the target price being set at $8.6.
G Sachs
G Sachs
Neutral
maintain
$63.3
2025-11-11
Reason
G Sachs
G Sachs
Price Target
$63.3
2025-11-11
maintain
Neutral
Reason
The article provides a list of stocks with their current prices, short selling data, and analyst ratings. All the listed stocks have a "Buy" rating, indicating that analysts believe these stocks are a good investment opportunity. The reasons for the "Buy" ratings are not explicitly stated in the provided text, but the presence of short selling data and the ratios may suggest that analysts see potential for price recovery or growth despite current short selling pressures. Additionally, the mention of "Order Momentum Remains Strong" for WUXI XDC implies that there is positive sentiment regarding its future performance, even though it has a neutral rating from G Sachs.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for 01177
Unlock Now

People Also Watch